All posts by medical

Cytovia Therapeutics, Inc Adds Two Industry Leaders to Its Board of Directors – BioSpace

NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces the appointment of Dr. Leila Alland and Ms. Jane Wasman to its Board of Directors, effective immediately.

Dr. Leila Alland brings extensive experience in oncology drug development to her role at Cytovia Therapeutics. Dr. Alland is currently Chief Medical Officer at PMV Pharma, a leader in the discovery and development of small molecule therapies targeting p53 mutations, which are prevalent in many cancers. Dr. Alland was previously Chief Medical Officer at Affimed, where she advanced the companys portfolio of clinical-stage immuno-oncology programs. During her career, she has held leadership positions at Tarveda Therapeutics, AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, and has contributed to numerous successful oncology drug approvals over the course of her career, spanning both molecularly targeted and immuno-oncology therapeutic products. Dr. Alland is a member of the Scientific Advisory Council of Columbia University's Center for Radiological Research. Dr. Alland obtained her medical degree from New York University School of Medicine, completed her residency in pediatrics at The Childrens Hospital of Philadelphia and her fellowship in pediatric hematology/oncology at The New York Hospital and Memorial Sloan-Kettering Cancer Center, and was Assistant Professor of Pediatrics at Albert Einstein College of Medicine. I am very excited to be joining the Board of Directors at Cytovia Therapeutics, said Dr. Alland. Cytovias portfolio of immune therapeutics is steeped in the science of NK cells and the development of powerful new technologies that leverage the ability of NK cells to fight cancer. These novel technologies have the potential to go far beyond current drug development paradigms and make a real difference to individuals living with cancer.

Ms. Jane Wasman is a strategic leader with almost 25 years in the biopharma industry, with extensive U.S. and international experience. Ms. Wasman is Chair of the Board of Directors of Sellas Life Sciences, a board member at Rigel Pharmaceuticals, and serves on the board of NY BIO. Ms. Wasman is Founder and President of JWasman Advisors, (a consulting firm focused on strategic, operational and corporate governance matters for biopharma and life sciences organizations). She previously served as President, International, General Counsel and Chief, Strategic Development at Acorda Therapeutics, where she led long-range planning and development in addition to international expansion and in leadership positions including Vice President at Schering Plough. Ms. Wasman graduated magna cum laude from Princeton University, and earned her J.D. from Harvard Law School. I am thrilled to be able to joinCytovia's team who is implementing an agile partnership strategy and capital-efficient execution approach, said Ms. Wasman. I believe Cytovia Therapeutics is positioned to become a leading NK company with a differentiated product portfolio, leveraging two strong technologies - CAR NK and NK engager antibodies.

Dr. Daniel Teper, co-founder, Chairman and CEO of Cytovia Therapeutics, Inc stated:"We are delighted to welcome two exceptional industry leaders to our boardof directors. Cytovia Therapeutics is at a growth inflexion point where it can fully benefit from Dr. Alland's solid track record in oncology drug development and Ms. Wasman's expertise in corporate and financial transactions."

Media Snippets accompanying this announcement are available by clicking on the images or links below:

ABOUT CYTOVIA THERAPEUTICS, INCCytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem and Macromoltek.

Learn more atwww.cytoviatx.com

Contact for media enquiries at Cytovia Therapeutics, IncSophie BadrVice President, Corporate AffairsSophie.badre@cytoviatx.com1(929) 317 1565

Read this article:
Cytovia Therapeutics, Inc Adds Two Industry Leaders to Its Board of Directors - BioSpace

How to safely deliver fertility treatments in the COVID-19 era: the controversy of guidelines – BioNews

29 June 2020

The Health Secretary's announcement on 1 May 2020 that fertility services in the UK could apply to reopen (see BioNews 1045) was a message of hope for all those who depend on fertility treatment for having a baby. Around the same time, various national and international scientific fertility societies published guidance on the 'safe' restart of the services during the coronavirus pandemic.

Fertility clinics in the UK had therefore the rather straightforward task of re-designing their practice protocols according to this COVID-19 guidance. Or perhaps this was not so straightforward?

As the medical director of a group of fertility clinics in the UK, I was assigned to design the new coronavirus-proof practice for my group. However, after starting to read the published guidelines, I soon realised that their recommendations were not as aligned as anticipated.

True, some of the recommended practice points were similar - mainly the use of social distancing and the use of personal protective equipment (PPE) by clinical staff. On the other hand, the guidelines approached the topic of testing for COVID-19 in their own different ways. For example, the European Society for Human Reproduction and Embryology (ESHRE) guidance recommended testing only for individuals who have symptoms or have had contact with someone with symptoms of COVID-19 infection, while the British Fertility Society and Association of Reproductive and Clinical Scientists (BFS-ARCS) advised to routinely test IVF patients for COVID-19, if a test is available.

When I investigated the availability of testing, I found out that indeed testing is available, but one had to research which tests are more reliable before deciding which one to go for. Moreover, the logistics of ordering the test, sending the sample to the laboratory and retrieving the result in time for the treatment had to be worked out.

I was so intrigued by the different approaches of the fertility guidelines, which prompted me to author an opinion paper about it, which has now been accepted in a reputable reproductive medicine journal.

Why is there such controversy among the guideline recommendations?

The inconsistencies in guidelines cannot be simply explained by geography. After all, these guidelines come from Europe (including the UK) and North America (USA and Canada), which have been experiencing similar challenges with coronavirus.

The answer is obvious; we simply do not know enough about the virus and we are still developing the relevant tests. More importantly, there is no experience how to best apply these tests in the fertility setting.

Guidance is, therefore, based mostly on expert opinion rather than scientific evidence.

It has to be acknowledged that fertility treatment is unique, in the sense that it lasts for a few weeks, during which one's good health needs to be continually re-affirmed. This is different to elective surgery, where a COVID-19 test can be scheduled just before admission.

One could hope to repeat the COVID-19 test every few days or before every visit to the fertility clinic. However, this is not practical for many reasons. The test often has to be outsourced to an external laboratory and inevitably takes at least a couple of days for the result to be available.

Testing introduces a substantial burden on the fertility services and staff resources, as well as an obvious financial burden for the paying party - whether this is the patient or the health authority.

Another concern has to do with the reliability of the test. No currently available test will pick up 100 percent of COVID-19 cases (current tests have approximately 70 percent sensitivity). This implies that, even if we performed the test repeatedly, we could still 'miss' some of the patients who carry the virus.

The absolute benefit of testing also has to do with how widespread the virus is in the community at any given point in time. At times of low infection rates, the chance of a COVID-19 test being positive is expected to be quite low.

Finally, there are other readily applicable measures, which help to reduce transmission (such as the social distancing and use of PPE); so, even if a patient carries the virus and doesn't know it, this does not mean they will definitely transmit it to others.

So, how should fertility clinics design their COVID-19 protocols for safety?

Until such time when enough experience has accumulated in the fertility sector, each clinic has to make its own decision how to go about it. Since there is no single full-proof test or intervention against coronavirus at the moment, combined measures are warranted. These measures should include social distancing when possible, PPE use, remote appointments, strict sanitation etc. Whether opportunistic COVID-19 testing should be part of the 'artillery' remains up to the individual clinic.

In my opinion, there are reasons for opting to apply more, rather than fewer, anti-COVID-19 measures at the restart.

Firstly, it is presumed to be safer to test, as doing a COVID-19 test can only detect more positive cases than not doing one. This will allow prompt cancellation of the treatment, thereby minimising the risk to others.

Secondly, testing allows the clinic to obtain important feedback on the usefulness of this approach, which could inform future policies. For example, if the test detects positive cases, it is obviously useful and should be continued (or even expanded). If, on the other hand, no positives are detected over a considerable number of sampled patients, this could make an evidence-based argument for discontinuing the test.

If a clinic chooses not to test, they can only learn the hard way, through trial and error; if they experience COVID-19 'clusters', their measures obviously allow enough COVID-19 cases to slip through (a 'cluster' is at least two positive individuals, patients or staff, who have had contact during the fertility treatment).

Other important metrics should also be internally monitored by clinics. The regional trends in infection rates as published by authoritative bodies - need to be regularly monitored. If the rates increase, it makes sense to tighten the anti-COVID-19 measures, which could include introducing - or re-introducing - a COVID-19 test.

Another important outcome to monitor is for the presence of clusters of positive cases within the same clinic. Clinics should be encouraged to report COVID-19 clusters that occur in their practice to the regulator - the Human Fertilisation and Embryology Authority (HFEA) - together with an action plan how they aim to minimise recurrence by strengthening their COVID-19 protocols.

Continue reading here:
How to safely deliver fertility treatments in the COVID-19 era: the controversy of guidelines - BioNews

In the NGSS, a Dogmatic Standard on Evolution – Discovery Institute

Inaccurate teaching about evolution is widespread, as Jonathan Wellss review of textbooks shows. The 2013 Next Generation Science Standards (NGSS, which most states have adopted verbatim or used to inform their science standards, are one sided on the issue as well.

Ive recently been perusing Proficiency Scales for the New Science Standards: A Framework for Science Instruction and Assessment, by Robert J. Marzano and David C. Yanoski. Marzano is a big name in education. The Marzano Framework and the Danielson Framework are the two most prominent teacher evaluation models. Proficiency scales are frameworks that help teachers grade students according to a state standard, to measure their progress of learning.

This book provides proficiency scales for each of the NGSS. Proficiency scales are generally on a 4-point scale, with a score of 3 meaning meets standard. 2. A score of 4 means a student demonstrates in-depth inferences and applications that go beyond what was taught according to Marzano. Scores lower than 2 demonstrate partial success at 2, with or without teacher help.

Id like to examine the proficiency scale for one of the most dogmatic standards on evolution in the NGSS:

Communicate scientific information that common ancestry and biological evolution are supported by multiple lines of empirical evidence (for example, communicate orally, graphically, or textually to give evidence for common ancestry and biological evolution such as similarities in DNA sequences, anatomical structures, and the order of appearance of structures in embryological development and to explain how each line of evidence relates to common ancestry and biological evolution).

What does Marzano list for score 2.0 criteria? The student will:

(a) Recognize or recall specific vocabulary (for example, anatomical structure, biochemical characteristic, biological evolution, common ancestry, degree of kinship, development, DNA sequence, embryological, evidence for unity of life, order of appearance, origin of life, phylogenetics, shared characteristic, similarity, structure).

(b) Describe similarities in DNA sequences, anatomical structures, and order of appearance of structures in embryological development of various organisms.

(c) Describe the process of biological evolution.

Lets analyze each of these in turn. For (a) some of these vocabulary terms are a great choice, but some are somewhat complex to define (origin of life or biological evolution, for example). More importantly, there are issues with using phylogenetics and embryological development as evidence for common ancestry and biological evolution. Okay, (b). Jonathan Wells (Icons of Evolution, Zombie Science both address this) and others have written extensively on homology and embryology in the past and how they fail to support evolution. And (c). Well, scientists are still trying to figure out how to describe the process of biological evolution. A student performing below standard is supposed to be able to do this? And what specifically is the student to describe neo-Darwinian theory? Genetic drift? Evo-devo?

The Marzano proficiency scales are undoubtedly used by a myriad of science teachers. At least on evolution, thats contributing to inaccurate education.

Photo credit:Yustinus Tjiuwanda viaUnsplash.

See the rest here:
In the NGSS, a Dogmatic Standard on Evolution - Discovery Institute

Surrogacy and human rights – Anna Dannreuther – UK Human Rights Blog

26 June 2020 by Guest Contributor

In Re X (Parental Order: Death of Intended Parent Prior to Birth) [2020] EWFC 39 the Family Court read down section 54 of the Human Fertilisation and Embryology Act 2008 to enable a parental order to be granted where an intending parent died shortly before the childs birth. This ensured the childs Article 8 and 14 rights were protected, and prevented much emotional hardship for this family.

The case has already been cited in Re A (Surrogacy: s.54 Criteria) M [2020] EWHC 1426 (Fam) as comprehensively setting out when a court may read down the statutory criteria in section 54.

Parental orders an introduction

Section 54 of the Human Fertilisation and Embryology Act 2008 enables two people to apply for a parental order over a child who has been born as the result of a surrogacy arrangement. A parental order transfers legal parenthood from the legal parents at the time of the childs birth (usually the surrogate and if applicable her husband or civil partner) to the intended parents.

Parental orders are recognised as having a transformative effect on the legal relationship between the child and the [intended parents]. The effect of the order is that the child is treated as though born to the applicants. It has a clear implication as regards the right to respect for family life under Article 8. A v P [2011] EWHC 1738 (Family), per Munby J [24].

The Facts

In this case, Mr and Mrs Y had struggled to conceive their own children, having undergone several unsuccessful IVF treatments, including using eggs donated from a friend. They then considered surrogacy and eventually met Mr and Mrs Z with whom they entered into a surrogacy agreement. The agreement set out the intentions of the parties, including that Mr and Mrs Y would apply for a parental order after the birth of the child. The resulting embryo consisted of Mr Ys sperm and Mrs Zs egg. Mr and Mrs Y and Mr and Mrs Z became closer during the pregnancy and it remained all four of the parties intentions that Mr and Mrs Y become the legal parents of the child.

Tragically, five months into Mrs Zs pregnancy, Mr Y died of heart failure. This left open the question of whether and how Mr and Mrs Ys status as legal parents of the child could be recognised, given the requirements of the statute that two applicants make the application, amongst other things. The child, X, was born four months later. Mrs Y brought an application for a parental order on behalf of herself and her late husband.[1] In her supporting statement, she said:

It is incredibly important to me to apply for a parental order. It is not just for myself or for [Mr and Mrs Z] (who have never intended to be her legal parents), but because I want her to have the surname [Y] and to have her father recognised. It will break my heart for her, and him, if it is not possible for [Mr Y] to be put on her birth certificate The way [X] was conceived was all about love, and [Mr Y] is and always will be her daddy. I know, had he been here, that he would never have stopped talking about her, and she would have made him so proud. She deserves to have a parental order which recognises him as her father, and I hope that the court will find a way to make it possible.

Summary of the Law

Section 54 HFEA contains several requirements that must be fulfilled before a parental order can be granted. Those at issue were:

While the applicants would easily have satisfied the statutory requirements if Mr Y were alive, his untimely death frustrated the courts ability to find these criteria clearly fulfilled.

Both the lawyers for the applicants, Natalie Gamble, and for the court-appointed guardian for the child, Ruth Cabeza, argued that the court should read down section 54 to ensure Xs human rights were protected. They referred to section 3 of the Human Rights Act 1998, which obligates courts to read primary legislation in a way that is compatible with Convention rights so far as it is possible to do so.

Theis J acknowledged that in certain circumstances section 3 required courts to read in words which change the meaning of the enacted legislation, so as to make it Convention-compliant, per Lord Nicholls in Ghaidan v Godin-Mendoza [2004] All ER (D) 210 at [32].

The question in this case was whether reading section 54 to enable a parental order to be made in respect of an intending parent who died before the child was born went with the grain of the legislation, or whether the scale of what is proposed would go beyond any implication that could possibly be derived from reading the existing legislation (per Lord Nicolls and Lord Roger in Ghaidan v Godin-Mendoza [33],[115]).

Section 54 human rights read downs

Section 54 has been subject to numerous human rights read downs. In A v P [2011] EWHC 1738 (Fam), Theis J had previously found that section 54 could be read down to allow an application where an intended father had died after the application had been issued, but before the order was made. In so deciding, Theis J focused on the transformative nature of a parental order, recognising that no other order can give recognition to [the childs] status in the same transformative way as a parental order can, and that a parental order would protect the identity of [the child] and the family unit in accordance with Article 8.

Non-compliance with the six-month time limit for making an application was also held not to prevent a parental order being made in Re X (A Child) (Surrogacy: Time Limit) [2014] EWHC 3135 (Fam).

While in the 2015 case of Re Z [2015] EWFC 73, the court found it could not read down the two applicant requirement to allow a single applicant to apply, that was because Parliament has expressly contemplated and rejected the idea that single applicants could apply. A declaration of incompatibility was therefore made, and Parliament subsequently enacted the Human Fertilisation and Embryology Act 2008 (Remedial) Order 2018, permitting single applicants to apply.

Submissions

The advocates submitted that, unlike in Re Z, there was no evidence that Parliament has ever considered the possibility of an intended parent dying during a surrogacy pregnancy, or that such a person should be excluded from obtaining a parental order. They further relied on the Joint Committee on Human Rights (JCHR) June 2018 report on the draft remedial order responding to Re Z, allowing single applicants to apply for parental orders, which had emphasised:

It is difficult to see the policy justification for seeking to distinguish between these different situations, or for placing such difficult emotional decisions on people with such significant potential impacts.

The two-applicant rule, the JCHR found, seems to introduce a new version of discrimination based on a new category without any justification. The advocates submitted this clearly signalled that the will of Parliament now seeks to ensure the law does not discriminate against different categories of applicants for parental orders on the grounds of relationship status. Further submissions were made drawing on provisions in the Human Fertilisation and Embryology Act 2008, whereupon legal parenthood status is acquired from the date of transfer of the embryo or artificial insemination.

It was submitted that these considerations supported the notion that it would go with the grain of the legislation to enable X to have Mr Y registered on her birth certificate.

Judgment

Theis J found that Articles 8 and 14 of the ECHR were clearly engaged in this case. While X was not able to establish a family life with her biological father prior to his premature death, the court was required to protect her Article 8 right to recognition of her identity as the child of her deceased father. Theis J relied on Munby Ps comments on section 54 in Re X, where he said:

Section 54 goes to the most fundamental aspects of status and, transcending even status, to the very identity of the child as a human being: who he is and who his parents are. It is central to his being, whether as an individual or as a member of his family. [] This case is fundamentally about Xs identity and his relationship with the commissioning parents. Fundamental as these matters must be to commissioning parents they are, if anything, even more fundamental to the child. [] A parental order, like an adoption order, has an effect extending far beyond the merely legal. It has the most profound personal, emotional, psychological, social and, it may be in some cases, cultural and religious consequences. [] any application for a parental order implicates both the childs right to family life and also the childs right to private life.

Theis J also reiterated that Article 8 rights include the right to adequate legal recognition of biological and social ties (citing D, G v ED, DD, A, B [2015] EWHC 911 (Fam)). She noted that Xs birth certificate currently names an individual (Mr Z) with whom she has no connection as her father.

Article 14 was found to be engaged on the grounds that Xs Convention rights should be secured without discrimination of any ground, including birth or other status. Without a parental order, X is unable to have a birth certificate that reflects the relationship and connection she has with Mr and Mrs Y as her parents, solely because of the circumstances of her birth through surrogacy.

Theis J found that reading down the legislation does not go against the grain of the legislation. To the contrary it provides the order that best meets a child born as a result of this type of arrangement.

Furthermore, no other order can accurately and properly reflect Xs identity. A child arrangements order or special guardianship order would grant Mrs Y parental responsibility limited to Xs minority, but it would not negate Xs legal relationship with Mr and Mrs Z and would result in her biological father being a legal stranger to her. An adoption order could only be applied for by Mrs Y acting alone. A failure of the law to recognise Xs connection with her biological father (by not granting a parental order) would amount to a breach of her Article 8 and Article 14 rights.

Theis J therefore read down the statute to enable the section 54 requirements to be met where an applicant dies after the childs conception but prior to its birth, where they would have been met immediately prior to the death. The court also determined, in line with section 1 of the Adoption and Children Act 2002, that the order met Xs lifelong welfare needs.

This meant that the court did not need to consider the childrens guardians arguments about the applicability of section 1 of the Law Reform (Miscellaneous Provisions) Act 1934, and about whether that provision needed to be read down.

Comment

This is another instance of the Human Rights Act 1998 remedying a potentially large injustice for the family involved. As Theis J recognised, these were compelling facts. X had been living with Mrs Y since birth, who had provided her with a loving home, and her birth had been planned long ago by Mr and Mrs Y who intended to be her lifelong, loving parents. The surrogate parents, Mr and Mrs Z fully supported Mr and Mrs Y in becoming Xs parents.

The fact that Mr Z died shortly before Xs birth frustrated the applicants ability to comply with the technical requirements of section 54. However, their case clearly fell within the intended ambit of section 54 applicants, not least because they so clearly fulfilled the section 54 criteria prior to Mr Ys death. The court rightly had no problem finding that reading down in this context went with rather than against the grain of the legislation, which was to protect commissioning parents against the unfairness of not having their legal parenthood and the familys origins recognised in the form of a parental order.

Although this is a narrow development of the law, it is a nonetheless welcome one for those who find themselves in such tragic circumstances.

Anna Dannreuther is a pupil barrister at Field Court Chambers. She assisted Ruth Cabeza who acted for the childrens guardian in this case. This article represents the views of the author only.

[1] There was a legal question as to the method by which this could be achieved, which was ultimately resolved by the courts reading down of the legislation. See paragraphs [58], [97].

Like Loading...

Originally posted here:
Surrogacy and human rights - Anna Dannreuther - UK Human Rights Blog

Global In Vitro Fertilization Market Next Big Thing | Major Giants Groupe Clinique Ambroise Par, amedes MVZ Cologne GmbH, AMP Center St Roch, AVA…

Data Bridge Market Research has recently added a concise research on the Global In Vitro Fertilization Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological development, new product launches and Industry competitive structure is elaborated.

Global In Vitro Fertilization Marketis expected to reach USD 847.8 billion by 2025, from USD 465.2 billion in 2017 growing at a CAGR of 10.0 % during the forecast period of 2018 to 2025. The upcoming market report contains data for the historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

To Remain Ahead Of Your Competitors, Request for a FREE Sample Here (with covid 19 Impact Analysis) @https://databridgemarketresearch.com/request-a-sample/?dbmr=global-in-vitro-fertilization-market

Major Market Competitors/Players:Global In Vitro Fertilization Market

Some of the major players operating in global in- vitro fertilization market are Groupe Clinique Ambroise Par, amedes MVZ Cologne GmbH, AMP Center St Roch, AVA International Clinic Scanfert, Bangkok IVF center, Betamedics, Biofertility Center, Bloom Healthcare, Bourn Hall Fertility Center, , Cardone & Associates Reproductive Medicine & Infertility, The Center for Advanced Reproductive Services, Chelsea and Westminster Hospital NHS Foundation Trust, Cloudnine Fertility, Conceptions Reproductive Associates of Colorado, Cyprus IVF Centre, Dansk Fertilitetsklinik, EUVITRO S.L.U., , Lieff Cabraser Heimann & Bernstein, LLP, Fertility First, IVF Centers Prof. Zech, Flinders Reproductive Medicine Pty Ltd, Genea Oxford Fertility Limited, IVF Spain, IVI Panama, KL Fertility & Gynaecology Centre, Lifesure Fertility and Gynaecology centre, Manipal Fertility, , Medfem Fertility Clinic, Monash IVF, OVA IVF Clinic Zurich, Procrea, RAPRUI S.r.l., SAFE FERTILITY CENTER, SANNO HOSPITAL, SIRM Fertility Clinics, Stork IVF Klinik, ARC-STER S.r.l., The Montreal Fertility Center, Thomson Medical Centre, TRIO Fertility, Virtus Health, VivaNeo, Die Kinderwunsch and among others.

Global In Vitro Fertilization Market,By Product (Reagents, Equipment),Type of Cycle (Fresh Non-Donor IVF Cycles, Frozen Non-Donor IVF Cycles, Frozen Donor IVF Cycles, Fresh Donor IVF Cycles), End User (Hospitals & Research Laboratories, Cryobanks ),Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Competitive Analysis:

The global In- Vitro Fertilization market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of In- Vitro Fertilization market for global, Europe, North America, Asia Pacific and South America.

Key Developments in the Market:

Buy this Report (Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries) @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-in-vitro-fertilization-market

Market Definition:

In vitro fertilization is a procedure in which egg from women ovary are removed and after that the egg is fertilized with a sperm in a laboratory procedure, and then the fertilized egg is transfered into the women uterus. In vitro fertilization is used in the management of female infertility. In 2018, the Cooper Companies was announce that the Cooper Surgical acquired the assets of The Life Global Group and its affiliates which is a leading provider of invitrofertilization devices. In July 2018, Merck launched new product Geri Assess 2.0.This product is useful in automatic detection of embryo and blastocyst development, improving efficiency in assessment.

According to the Centre for Disease Control and Prevention in 2016, approximately 263,577 ART (Assisted Reproductive Technology) cycle was performed in US. As per the Human Fertilization and Embryology Authority in 2016, more than 68,000 IVF treatments were provided in U.K. In 2016 Birth rate from IVF has been increased to 85.0% in U.K. In 2016 around 20000 childrens were born by IVF. As per the published news IVF Success Rates For Fertility Clinics in the United States in 2016 and around 263,577 ART cycle was performed in U.S. Due to the increasing rate of infertility amongst the population, patients are opting the IVF Fertilization which is fuelling the growth of market.

Major Market Drivers and Restraints:

Market Segmentation:

The global In vitro fertilization market is segmented based on product, type of cycle, end user and geographical segments.

Based on product, the market is segmented into reagents, equipment.

Based on reagents, the market is further segmented into embryo culture media, cryopreservation media, sperm processing media, OVUM processing media.

Based on equipment, the market is further segmented into imaging systems, sperm separation systems, cabinets, OVUM aspiration pumps, incubators, micromanipulator systems, gas analysers, laser systems, accessories, cryo systems, anti-vibration tables, witness systems.

Based on type of cycle, the market is segmented into fresh non-donor IVF cycles, frozen non-donor IVF cycles, frozen donor IVF cycles, fresh donor IVF cycles.

Based on end user, the market is segmented into fertility clinics & surgical centers, hospitals & research laboratories, cryobanks.

Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:[emailprotected]

Read the original post:
Global In Vitro Fertilization Market Next Big Thing | Major Giants Groupe Clinique Ambroise Par, amedes MVZ Cologne GmbH, AMP Center St Roch, AVA...

Transgender women ‘should be allowed womb transplants so they can have own babies’ – Mirror Online

Transgender women should be entitled to womb transplant to enable them to have their own babies, according to a leading British surgeon.

Two years ago a woman in Brazil became the first mother to give birth to her child using a womb transplanted from a deceased donor to a woman.

It was a major breakthrough in fertility medicine when the little girl was born healthy and weighing 5.6lbs.

It comes just four years after the worlds first womb transplant baby from a live donor was born in Sweden in 2014.

Surgeon Christopher Inglefield, founder of the London Transgender Clinic, says a successful uterus implant into a trans-female is now achievable.

He says the procedure essentially identical to that of cis-women - aka females born in that gender.

Mr Inglefield, a specialist in gender confirmation surgery as well as facial and body feminisation, said: This pioneering birth is extremely important for any trans female who would like to carry her own child.

Because once the medical community accept this as a treatment for cis-women with uterine infertility, such as congenital absence of a womb, then it would be illegal to deny a trans-female who has completed her transition.

"There are clearly anatomical boundaries when it comes to trans women but these are problems that I believe can be surmounted and the transplant into a trans-female is essentially identical to that of a cis-female.

The Human Fertilisation and Embryology Authority (HFEA) confirm there are no regulations in place to prevent a trans woman who has received a uterus transplant from having IVF treatment.

And Mr Inglefield describes how a transplant would work.

He explained: "The most important step is the harvesting from the donor as great care is required to avoid damage to the arteries and veins supplying the uterus.

"The actual plumbing in is straight forward.

"The donor vessels are connected to the pelvic artery and veins which are the same in both males and females.

"With a uterus transplant in a trans-female, the neovaginal would be opened at the pelvic end to accept the donor womb.

"And the same procedure is used in a cis-female transplant with the donor uterus being attached to the native vagina.

Trans females have a much narrower pelvis than cis-women of the same height, but there would still be room for them to carry a child.

Supplemental hormones could be taken to replicate the changes that occur in the body when a woman is pregnant.

Meanwhile its highly unlikely that a trans female would give birth naturally, but would be delivered via Caesarian section in order to safeguard the child.

Other experts have also endorsed Mr Inglefields claims.

In November last year, Dr Richard Paulson, former president of the American Society for Reproductive Medicine, said there was no anatomical reason why a womb could not be successfully implanted into a transgender woman.

He added: "You could do it tomorrow. There would be additional challenges, but I dont see any obvious problem that would preclude it.

"I personally suspect there are going to be trans women who are going to want to have a uterus and will likely get the transplant.

Womb transplant surgery is being seen as a major cause for hope for those who suffer from Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome.

This is when a woman fails to develop a proper uterus and vagina yet has normal ovarian functions and normal external genitalia.

Women who have MRKH will still go on to develop breasts and pubic hair, but they will not have a menstrual cycle.

The syndrome is thought to affect around 1 in every 4,500 women.

But Mr Inglefield, who appeared in ITV's fly-on-the wall documentary Transformation Street, says the demand among trans women could be far greater.

He added: According to some estimates, the prevalence of transgender females in the UK could be as high as 1,000 per 100,000 persons, around 1 per cent of the population.

Just looking at the potential number of trans females who might seek uterine transplantation surgery and its abundantly clear it could become a vital medical service.

As it stands, trans women face a tricky pathway to motherhood, which is often achieved through surrogacy, adoption or fostering.

But those pathways are not without their own pitfalls and many would-be mothers simply long to carry their child, to be pregnant in the very real sense.

As womb transplant surgery is further improved and perfected, its vital trans women are not excluded from the conversation, at it could immeasurably improve a great many lives.

The Gender Recognition Act 2004 says that a trans female can apply for a Gender Recognition Certificate if they wish for their acquired gender to be legally recognised in the UK.

Applicants must go before a panel, documenting any treatments theyve had to change their sexual characteristics, such as hormone treatment or surgery.

They must have lived in their acquired gender for at least two years if single, or six years if married or in a civil partnership.

A spokesperson for the HFEA said: "I can confirm that to our knowledge there are currently no regulations in place which would prevent a person who has received a uterus transplant from having IVF treatment.

"The law, as it currently stands, does not require the person who is carrying a child to have obtained a GRC stating that they are female before having their fertility treatment.

And as stated in the Act the person who carries or has carried a child as a result of an embryo transfer, or artificial insemination, is considered as the mother of the child at birth."

The new test case, which has made headlines across the world, saw a 32-year-old woman born without a uterus given one taken from a 45-year-old donor who died from a brain haemorrhage.

The donor womb was implanted in a 10 hour surgery, which saw veins, arteries, ligaments and vaginal canals being connected.

And she then received fertilised eggs produced by IVF.

The birth took place in December 2017, but has only now been reported in journal The Lancet.

There have been 39 womb transplants across the world and of these, 11 babies born.

Until the Brazil transplant the surgery had failed 10 times.

The womb donor was a mum-of-three, who was in her mid-40s and died from bleeding on the brain.

Just six weeks after the surgery, the woman who received the womb started having periods.

Then, seven months later the eggs, which had been fertilised via IVF, were implanted in her womb.

Her baby was born by caesarean secion on December 15, 2017, and weighed 6lb.

Dr Dani Ejzenbery, from Hospital das Clicas in Sao Paulo, where the surgery was carried out, said: "The first uterus transplants from live donors were a medical milestone, creating the possibilty of childbirth for many infertile women with access to suitable donors and the needed medical facilities.

"However, the need for a live donor is a major limitation as donors are rare, typically being willing and eligible family members or close friends."

Imprial College London's Dr Srdjan Saso described the surgery as "extremely exciting".

The government equalities office estimates there are between 200,000 to 500,000 trans people in the UK.

See the original post:
Transgender women 'should be allowed womb transplants so they can have own babies' - Mirror Online

A ‘quick and easy’ COVID-19 test developed for population-scale screening – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Jun 24 2020

Global endeavors to fight the Covid-19 pandemic heavily rely on accurate, fast and frequent tests for the coronavirus SARS-CoV-2 - "test, test, test", as the World Health Organization (WHO) has bluntly put it. Around the globe, the prevailing approach to diagnose acute infections is based on real-time qPCR, a method that amplifies and detects viral nucleic acid molecules in samples obtained from nose and throat swabs. However, qPCR requires sophisticated and expensive equipment and specialist staff to operate it - crucial drawbacks for example in remote or low-resource settings.

Scientists from the Vienna BioCenter and collaborators have now pushed an established nucleic acid detection assay to a new level. The so-called "Loop-mediated isothermal amplification (RT-LAMP)", first developed twenty years ago, is cheap, simple and quick - features that make it in principle an ideal alternative for routine SARS-CoV-2 detection. However, limited sensitivity and robustness have so far held back RT-LAMP-based assays from entering the center stage for SARS-CoV-2 diagnostics. The improvements introduced by the Viennese team overcome these challenges and make RT-LAMP a potential game-changer for population-scale screening approaches, especially in economically disadvantaged countries.

Starting with a 5-minute lysis step that "breaks open" cells and virus particles, RT-LAMP employs a simple reaction in which the viral RNA is converted into DNA and amplified billionfold within less than 30 minutes. The generation of such tremendous amounts of DNA can be directly observed with the naked eye by a visual colour change from purple to sky-blue in the reaction tube. Combining this method with a simple RNA enrichment step is at the heart of the newly developed method as it boosts sensitivity by orders of magnitude. Neither specialist laboratory equipment nor expert skills are needed - the most challenging step is to keep the sample at a stable temperature of approximately 63C during the 30 minutes of the reaction, a task that can - if necessary - be fulfilled by re-purposed kitchen devices.

Our method builds on existing protocols developed for pathogen detection. For SARS-CoV-2-detection, we managed to improve it to a level that matches qPCR-like sensitivity on crude patient samples. We are extremely excited and can barely wait to see it applied. We expect that these improvements, including the ability to perform pooled screening, will make a real difference not only in developing countries, but in low-resource environments anywhere in the World. Sensitive, affordable and rapid SARS-CoV-2 screening and diagnostics approaches are much needed now."

Julius Brennecke of the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences

"The way this whole project unfolded is rather exceptional," says Andrea Pauli of the Research Institute of Molecular Pathology (IMP). "It started off as a crazy idea, triggered by our believe that as scientists we must act to help in the current pandemic. Through a remarkable coincidence, Max Kellner, an Austrian PhD student at the institute LMB in Cambridge who had prior experience with isothermal amplification methods, got stranded in his hometown Vienna during the lockdown. When we found out, we teamed him up with Vienna BioCenter PhD students Julian Ross and Jakob Schnabl. And so, two groups, normally working on Drosophila oogenesis and zebrafish embryology, came together and set foot in a new field. An exceptional level of team spirit and enthusiasm allowed us to push this project much further than we had ever envisioned and made it a once in a life-time experience for everyone involved."

IMP and IMBA are members of the Vienna BioCenter, and the breakthrough is testimony to the fruitful and collaborative spirit this campus is known for. The lockdown period boosted these synergistic activities in an unprecedented manner across labs and institutes. While normal research activities have returned to the labs by now, scientists across campus continue to contribute their time and expertise to combat the outbreak of the Covid-19 pandemic. As part of the VCDI (Vienna Covid-19 Diagnostics Initiative) they work jointly on questions that open the door for applications which could benefit millions of people around the world.

The study underlying this news item will be uploaded to the preprint service bioRxiv, where it is expected to become available soon.

Link:
A 'quick and easy' COVID-19 test developed for population-scale screening - News-Medical.Net

Racism Is a Health Crisis. Why Aren’t We Treating It Like One? – Healthline

After 5 days of protests against police brutality in Columbus, Ohio, the city council organized a virtual meeting and introduced a resolution to classify racism as a public health crisis.

Joining that meeting was Ohio State University (OSU) President Michael V. Drake, who gave his unqualified support to the resolution.

The burden of being Black in America is not only exploding in our bodies, its spilling into the streets. If we dont begin treating this as a health crisis, our communities will never heal, said Drake, who then committed the universitys staff and resources toward addressing the issue.

Dr. Nwando Olayiwola, chair of the department of family medicine at The Ohio State University Wexner Medical Center, admires how Drake called racism a health crisis.

There are many institutions across the nation that are still not comfortable actually saying that, so I think calling it by its name is hugely important as a first [step] to addressing it, Olayiwola said.

In the medical community, theres a growing body of research confirming that racism, in addition to being a societal ill, is indeed a public health crisis, one that has been hard to ignore with the arrival of COVID-19.

The pandemic has revealed stark disparities among racial lines in health outcomes. Death rates for Black and Hispanic/Latino people are significantly higher in every age category, according to data from the Centers for Disease Control and Prevention (CDC).

The disparity is especially apparent in younger brackets. Death rates of Black and Hispanic/Latino people ages 45 to 54 are at least six times higher than rates for white people.

While geography may play some part in these disparities, there are deeper forces at work.

A study released in February from Auburn University found that racist encounters caused sustained stress among a group of African Americans, which in turn led to cellular aging.

David Chae, ScD, who helmed the research team, called racism a social toxin that becomes embedded at the cellular level.

This would help explain why, for example, Black men continue to have shorter life expectancies than white men (72.2 years vs. 76.6 years, respectively, in 2011, according to the CDC).

Stress stemming from biased encounters is far from the only factor that leads to shorter life spans.

Racism is a multisystem agitator, said Wizdom Powell, director of the Health Disparities Institute and associate professor of psychiatry at UConn Health.

Its many tentacles are wrapped around the policies, practices, and procedures that govern (and harm) Black lives, she says.

There is more than enough evidence to affirm that racism in all of its myriad forms has significant detrimental impacts or implications for the health of Black Americans, Powell said.

Racisms harm to health is both physical and mental. Experiencing an act like racial profiling or a microaggression can lead to a higher risk of depression, anxiety, and trauma for a Black person.

A 2019 study from UCLA and University of Southern California scientists showed that the toxic effect of stress caused by racism can trigger an immune system response that increases chronic inflammation in Black people, which in turn causes a host of health problems like heart disease and metastatic cancer.

The redlining of neighborhoods across the country had led to ongoing segregation and poorer quality environments and education for many communities of color.

Numerous studies equate higher education with less stress and longer life spans. Wealth is also tied to better health, leaving a bleak outlook for those with few opportunities for employment and upward mobility.

Long histories of discrimination sow distrust in institutions among people of color. And this spills over into the healthcare system.

If you experience a lot of racism in your everyday life, youre more likely to believe, and rationally so, that you could experience the same racism while trying to get your healthcare needs met, Powell said.

This perception is earned. Research has shown that healthcare providers treat Black patients differently than white patients.

A 2010 study found that physicians are more likely to recommend a cardiac procedure to white patients presenting with the same symptoms as Black patients. Nonwhite patients also receive less pain relief in emergency rooms, according to a 2019 report that listed implicit bias as a factor.

Racism isnt just a figment of peoples imagination or an attitudinal challenge, Powell said. Its actually one thats rooted in an unfortunate reality, and thats that Black folk dont always get equal treatment and equal quality care.

The United States has a long history of medical malice, says Powell, most infamously the Tuskegee experiment conducted by the U.S. Public Health Service in which Black men unbeknownst to them were observed for untreated syphilis for decades.

Horrific abuses, from slavery to present day, fill books like Medical Apartheid by Harriet A. Washington and Bones in the Basement by Robert Blakely and Judith M. Harrington.

Powell worries even today about how well-intentioned providers in the current pandemic may be making decisions based on implicit bias, such as where to allocate a ventilator or other lifesaving medical resources.

While theres no study to back up this concern, Olayiwola attests that not all providers are as committed as OSUs president to the belief that racism is a health crisis.

I wish I could say that that these physicians feel thats a problem, but Im confident that thats not true, Olayiwola said.

Recently, OSUs department of family medicine, which she chairs, hosted an open dialogue where several doctors expressed that they remained unconvinced of this connection.

Because racism is a deep-seated issue that touches every institution, it requires a complete system change, one that transforms spaces where people live, work, play, pray, get educated, and get healthcare, Powell said.

I always talk about racism as a virus, Powell said, noting parallels between the work of containing an outbreak and stamping out bias at every level.

For an institution, the first step is calling racism a health crisis, as OSU has done. Then comes a plan of action for addressing it.

To this end, an institution can conduct an internal review of its practices in employment, promotion, and, in OSUs case, its selection of students and curriculum.

While all medical students undergo implicit bias training, for example, Olayiwola believes far more can be done to teach about racism in medical education, just as we would embryology and understanding the genesis of a human being.

Youre doing a self-examination on an X-ray, if you will, of your own performance, and mitigating or eliminating any of the disparities that you find, Olayiwola said.

After an internal review comes the external work of investing in communities. OSU infused economic vibrancy in communities of color by building health facilities, increasing employment opportunities, and launching education programs.

And even more importantly, it has the recognition that we can do better, no matter how well we think were doing, Olayiwola said.

Of course, improvement or reform may not always be the answer.

Reform suggests that there is something meritorious in the design in the first place. And in many instances, thats the case. But there are circumstances and systems where that call for something more radical, Powell said.

In the wake of the killing of George Floyd, protestors are demanding a dismantling of the police, which institutionally began as a slave patrol in the United States.

I am hard-pressed to imagine, or try to reimagine, how we could rebuild that, Powell said.

Healthcare has its own advocates for a rebuilding.

But there are also areas for reform to ensure greater access to care for Black people and all vulnerable people, including increasing access to care regardless of employment status and other hurdles that disproportionately affect people of color.

On a local level, communities can reallocate budgets to spend less money on law enforcement and more on resources for mental health.

In an ideal world, a counselor, not a cop, can be called to help a child after an angry outburst. Police are ill-equipped to deal with people dealing with mental health issues, and prisons are no substitute for treatment centers.

Schools can also be resource centers to help young people cope with trauma, be it intergenerational or rooted in the pandemic, police shootings, and protests that have shook the nation.

In Los Angeles, students are marching to demand the removal of police who patrol the public schools in favor of funding college counselors, mental health services, nurses, and more programs.

This could be just the beginning of the conversation in creating an anti-racist school environment.

Community groups are key in this fight.

The Center for African American Health provides a wide range of essential resources in the Denver area. It connects individuals and families with general services like food and clothing, parental support, employment, and transportation, as well as education programs in parenting, aging, health insurance literacy, and nutrition.

These groups need committed leaders, volunteers, and resources. When Deidre Johnson joined as CEO and executive director nearly 5 years ago, she expanded the organizations scope to become a family resource center.

The goal was, how can we start earlier in the life span so that were not managing diseases but starting to prevent them altogether? Johnson said. Having changed our model, we really are working to help people have better access to all the social determinants.

Local groups also have the ability to convey the Black communitys needs to positions of political power.

A social movement maintained by the center, BeHeard Mile High, surveys Black Denver-area residents on issues related to health that are shared with policymakers.

Recently, the group was able to collect more than 500 responses about COVID-19 from Black residents after the state failed to collect many responses from Black people on its own invaluable data that spotlighted the crisis in this community and will help address it.

Youve got to be flexible, Johnson advised other groups looking to serve communities of color.

COVID-19, for example, spurred the center to pivot suddenly in its services. It began distributing personal protective equipment as well as funds to help people pay food and rent.

We were the only ones that were doing it for the African American community in Denver, Johnson said with incredulity. Im glad that we were there. Were still raising more, but we got way more requests than we had the ability to handle.

This is not a problem that cannot be solved, Powell said. Race is a sociological invention. The circumstances and experiences linked to race are very real, and the structural barriers produced by race are real. The violence against community in the name of race are real, but race itself is fictitious.

Be active in seeking out information and resources that others have already prepared.

Think about how you can use a platform to create an ant-racist culture. This could be at work or even at the dinner table, where conversations with children and family members can turn into an opportunity to learn from this moment and grow.

This gets in the way of a lot of substantial action, Powell said. As a psychologist, I can tell you its normal and appropriate in some instances, but too much of that will paralyze you.

Donating even a small amount to organizations that are supporting Black communities and advocating for social justice, like the Center for African American Health, can make a big difference.

Beyond donating, contact an organization to see what volunteer support is needed.

Reach out, but dont reach out with assumption that you know whats needed. Just reach out and ask how you can be of service, Johnson advised.

This could mean voting for them, engaging in mentorship opportunities, or giving up a seat at the table.

My liberation is bound up in yours. If Im not free, youre not free, Powell said. If theres a racial injustice Im experiencing, then were all living in a racially unjust world.

Breathe, baby, breathe. I would say to everyone, because this is heavy, Powell said.

Not everyone will be able to attend in-person protests and demonstrations, especially in the middle of a pandemic.

Theres many paths to the revolution, Powell said. Hers is scholarship; for others, it might be writing, giving, or having those tough conversations.

We owe it to them to ensure that, while were fighting the unnecessary fights, that we are pouring love back into our children and reminding them they matter, that their lives matter, their words matter, their existence matter, Powell said.

In many ways, without them, the future of our nation will be compromised. So we have to hold space for our children as we are holding space for our own pain, anger, and grief, she said.

Here is the original post:
Racism Is a Health Crisis. Why Aren't We Treating It Like One? - Healthline

Ophthalmology, Visual and Anatomical Sciences ranks 11th in the nation, No. 1 in Michigan in NIH research funding – The South End

The Wayne State University School of Medicines Department of Ophthalmology, Visual and Anatomical Sciences ranks 11th in the nation and No. 1 in Michigan medical schools in National Institutes of Health research funding.

The Blue Ridge Institute for Medical Research, which provides an annual ranking of NIH funding to medical schools and individual departments, this year placed the WSU department 11th among the nations academic Ophthalmology departments.

In 2019, the department secured $8,014,848 in NIH research funding, making it the leading Ophthalmology department among Michigans medical schools in that category.

In 2018, the Department of Ophthalmology merged with the Department of Anatomy and Cell Biology to create the new Department of Ophthalmology, Visual and Anatomical Sciences. Research in the department encompasses major areas of vision and neurosciences, focusing on the retina and other areas of the brain and spinal cord in addition to infectious diseases of the cornea and retina.

The department is a center of excellence in vision and holds both a National Eye InstituteP30 grant renewed for years 36 through 40 in 2019 and a Research to Prevent Blindness grant.

Clinical activities take place at the Kresge Eye Institute, which excels in all areas of ophthalmology, with major strengths in retina, glaucoma, infectious diseases and cataracts. The Kresge Eye Institute is considered one of the nation's leading medical centers for the preservation of sight and has an international reputation for pioneering eye research programs.

The Blue Ridge Institute for Medical Research has monitored NIH funding to medical schools and other health science schools and organizations since 2006. It generates an annual ranking of NIH funding for United States medical schools and their departments.

See more here:
Ophthalmology, Visual and Anatomical Sciences ranks 11th in the nation, No. 1 in Michigan in NIH research funding - The South End

Why Sandra Oh Wanted to go from ‘Grey’s Anatomy’ to ‘Scandal’ – Showbiz Cheat Sheet

Greys Anatomyfans are holding out hope that Sandra Oh, who portrayed Dr. Cristina Yang from 2005 to 2014, will reprise her role on the medical drama. Now killing it in her role on BBC Americas psychological thriller Killing Eve,the formerGreysstaris making no promises of returning to the halls of Grey Sloan Memorial.

Oh recently revealed that whileon the hit ABC show, she came across another character from Greys creator Shonda Rhimes that greatly piqued her interest.

Receiving critical acclaim including a Golden Globe for her role as British intelligence investigator Eve Polastri on the BBC America series, Oh is thriving in the thriller genre.

Killing Evewas the right series at the right time for me. I really love the show, I like the style of it, I like the thriller aspect, Oh toldThe Sydney Morning Heraldin April. I also like being able to play a character who is able to express not only a rainbow of emotions, but also a lot of depth.

Assigned to capture psychopathic assassin Villanelle (played by Jodie Comer), Eve breaks out of the boredom of her life through the dangerous cat-and-mouse hunt. Oh feels that Eves place in life resonates with viewers.

RELATED:What Greys Anatomy Alum, Killing Eve Star Sandra Oh Says On Having Children

I think people can identify with how this woman finds a renewed spark in life. Shes a woman in the middle of life, who is stagnating in some way in her work, where she does a decent job, the Greys alum explained. Shes not really curious, shes not really paying attention and shes not a really vital or dynamic person. But we see the spark of life that emerges from her.

Premiering in April 2018, Killing Eve soon became Must See TV. Oh was attracted to the many aspects of the character, where some facets stood out more than others.

There are other elements of the series that I really love, which are the international locations, the overall style of it, or genre of it, Oh shared. But the fact that you have a middle-aged lady who is very determined but doesnt know exactly what she is doing that really fascinated me.

Always striving to portray characters of depth, Oh was intrigued by Eves multi-layered persona.

RELATED:Sandra Oh Describes Her Last Day on Greys Anatomy

I like Eves vulnerability and I spent a lot of this show being scared. And I thought that was also very interesting, the Golden Globe winner explained. Its not so much that I consciously seek out characters who are determined or confident. Im interested in what takes them to where they want to go. I will give my all to get that character to that place.

In an interview for the Variety series Actors on Actors, Oh recently spoke to actress Kerry Washington on coming across the script for the very first showing of Scandal, where Washington played main character Olivia Pope. With the political drama centered around Olivia, a Washington, D.C. fixer, Oh was tempted to trade in her scrubs from Grey Sloan Memorial for an attorneys suit.

I was on Greys. We were on stage five, Oh recalled to Washington of seeing the initial Scandal script. Someone snuck it to me, I dont know who it was, but I got my hands on that pilot and I read it and I was just like, How could I play Olivia Pope?

Oh found the character so compelling that she asked Greys creator Rhimes if she could pull double duty on both shows. I remember going to Shonda, and its like, How could I do this? What is this script? Could I do this too?' Oh recounted.

Apparently, Rhimes wasnt on board with the idea. She goes, No, youve got to play Cristina Yang! Oh shared. But I also feel like its so wonderful and rare when you get in your hands something that you know is electric, that you can feel.

Despite Rhimes rejecting Ohs request, the Killing Eve star recognized that Washington was meant to play Olivia. Im so glad it was you, Oh told the Scandal star.

Go here to see the original:
Why Sandra Oh Wanted to go from 'Grey's Anatomy' to 'Scandal' - Showbiz Cheat Sheet